Andrew C Orth's most recent trade in Krystal Biotech Inc was a trade of 12,500 Common Stock done at an average price of $63.6 . Disclosure was reported to the exchange on June 9, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Krystal Biotech Inc | Andrew C. Orth | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 63.55 per share. | 09 Jun 2023 | 12,500 | 12,600 (0%) | 0% | 63.6 | 794,375 | Common Stock |
| Krystal Biotech Inc | Andrew C. Orth | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jun 2023 | 12,500 | 37,500 | - | - | Stock Option (Right to Buy) | |
| Krystal Biotech Inc | Andrew C. Orth | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 128.94 per share. | 09 Jun 2023 | 6,906 | 433 (0%) | 0% | 128.9 | 890,488 | Common Stock |
| Krystal Biotech Inc | Andrew C. Orth | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 128.10 per share. | 09 Jun 2023 | 5,261 | 7,339 (0%) | 0% | 128.1 | 673,958 | Common Stock |
| Krystal Biotech Inc | Andrew C. Orth | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 129.70 per share. | 09 Jun 2023 | 333 | 100 (0%) | 0% | 129.7 | 43,189 | Common Stock |
| Krystal Biotech Inc | Andrew C. Orth | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2023 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Krystal Biotech Inc | Andrew C. Orth | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2023 | 10,000 | 10,000 | - | - | Performance Stock Units | |
| Krystal Biotech Inc | Andrew C. Orth | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) |